FirsthandHealth
gov.uk: Medicines and Healthcare products Regulatory AgencyUnited Kingdom19 November 2026

MHRA Appoints Steven Davies as Chief Finance and Commercial Officer

On 19 November 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) announced the appointment of Steven Davies as its new Chief Finance and Commercial Officer. The MHRA is the government agency responsible for regulating all medicines and medical devices in the UK to ensure they work and are acceptably safe. Davies brings 25 years of health sector experience, joining from his position as Chief Financial and Investment Officer at Guy’s and St. Thomas’ NHS Foundation Trust. For everyday readers, this leadership change connects directly to how quickly and safely new treatments reach patients. The MHRA is preparing to implement its five-year 2030 Strategy, which involves investing in laboratories and technology to accelerate drug approvals and monitor emerging health risks. Davies will oversee financial management, major capital investments, and commercial plans designed to attract life sciences investment to the UK.

What was announced

On 19 November 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that Steven Davies will join as its new Chief Finance and Commercial Officer. The MHRA is an executive agency of the Department of Health and Social Care responsible for regulating all UK medicines and medical devices to ensure safety and effectiveness.

Davies has worked in NHS finance since 2000, when he started in the national finance graduate scheme. His 25 years of experience include serving as Chief Financial Officer and Deputy Chief Executive at Moorfields Eye Hospital NHS Foundation Trust. He leaves his current role as Chief Financial and Investment Officer at Guy’s and St. Thomas’ NHS Foundation Trust to take up the MHRA post.

What it means

Davies will manage the MHRA's financial management, major investments, and commercial plan as the agency implements its 2030 Strategy.

MHRA Chief Executive Lawrence Tallon said Davies will oversee capital investments in technology and laboratories, manage agency revenue streams, and adjust the funding model for medical innovators. Tallon noted that the goal is to create a regulatory system that attracts life sciences investment to the UK.

MHRA Chair Professor Anthony Harnden added that Davies' experience will support efforts to speed up treatment approvals, monitor emerging health risks, and keep safety rules aligned with scientific progress.

What the announcement does not tell us

The MHRA did not state when Davies will officially start in the new role. The announcement also leaves out several operational and financial details:

  • The specific monetary values of the planned capital investments in laboratories and technology.
  • How the funding model for innovators will be changed.
  • The specific regulatory changes planned to encourage inward investment in life sciences.
  • Who will succeed Davies at Guy’s and St. Thomas’ NHS Foundation Trust.

How this was written

This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is gov.uk: Medicines and Healthcare products Regulatory Agency’s own. Always check the original before acting on anything here.

The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed a new Chief Financial and Commercial Officer to drive forward the financial aspects of its new five-year strategy.
Source: gov.uk: Medicines and Healthcare products Regulatory Agency

More from gov.uk: Medicines and Healthcare products Regulatory Agency

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.